West Pharmaceutical Services said consolidated net sales for the quarter ended June 30, 2025 increased $64.4 million (9.2%) from the same period in the prior year, including a favorable foreign currency translation impact of $16.5 million. Excluding foreign currency translation effects, consolidated net sales increased $47.9 million (6.8%).

10-QQuarterly reportFiled Jul 24, 2025Period of report Jun 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

West Pharmaceutical Services said consolidated net sales for the quarter ended June 30, 2025 increased $64.4 million (9.2%) from the same period in the prior year, including a favorable foreign currency translation impact of $16.5 million. Excluding foreign currency translation effects, consolidated net sales increased $47.9 million (6.8%).
The company said Proprietary Products net sales for Q2 increased $60.1 million (10.7%), and gross profit margin rose 3.1 margin points. It cited higher plant absorption from increased customer demand and sales price increases as factors.
West Pharmaceutical Services said consolidated gross profit for Q2 2025 increased $43.9 million (19.1%) from the same period in the prior year, and consolidated operating profit increased $27.5 million (21.8%). Consolidated gross profit margin rose 2.9 margin points.
The company said net cash provided by operating activities for the 6 months ended 2025 increased $23.3 million, and net cash used in financing activities decreased $327.4 million. During the same period, it repurchased 552,593 shares for a total of $134.0 million.

Key figures

Quarter ended June 30, 2025

Revenue: $766M
Operating income: $154M
Net income: $132M
EPS: $1.82
Gross profit: $274M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Consolidated Net Sales Increase for Q2 2025

West Pharmaceutical Services said consolidated net sales for the quarter ended June 30, 2025 increased $64.4 million (9.2%) from the same period in the prior year, including a favorable foreign currency translation impact of $16.5 million. Excluding foreign currency translation effects, consolidated net sales increased $47.9 million (6.8%).

Source · Based on the MD&A text of the filing

Proprietary Products Net Sales and Gross Profit Margin

The company said Proprietary Products net sales for Q2 increased $60.1 million (10.7%), and gross profit margin rose 3.1 margin points. It cited higher plant absorption from increased customer demand and sales price increases as factors.

Source · Based on the MD&A text of the filing

Consolidated Gross Profit and Operating Profit for Q2

West Pharmaceutical Services said consolidated gross profit for Q2 2025 increased $43.9 million (19.1%) from the same period in the prior year, and consolidated operating profit increased $27.5 million (21.8%). Consolidated gross profit margin rose 2.9 margin points.

Source · Based on the MD&A text of the filing

Cash Flows and Share Repurchases for 6 Months

The company said net cash provided by operating activities for the 6 months ended 2025 increased $23.3 million, and net cash used in financing activities decreased $327.4 million. During the same period, it repurchased 552,593 shares for a total of $134.0 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.